Bridgeworth’s Teva Pharmaceuticals TEVA Stock Holding History

Bridgeworth’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,700	Closed	-$41K	–	488
2018 Q2	$41K	Buy	+1,700	New	+$34.7K	0.02%	307

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bridgeworth's TEVA Position: Q3 2018 in Review

Bridgeworth sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 1,700 shares — an estimated $41K sold.

Bridgeworth first reported a position in TEVA in Q2 2018 and held it in 1 quarter. The position peaked at $41K in Q2 2018. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

Bridgeworth reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Bridgeworth sold 1,700 Teva Pharmaceuticals shares in Q3 2018, an estimated $41K.
Bridgeworth first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Bridgeworth's Teva Pharmaceuticals position peaked at $41K in Q2 2018.
556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Bridgeworth's 13F filing for Q3 2018, filed 13 Nov 2018.